AnsunBiopharma CEO and leadership

Nancy Tang Chang (born 1950), née Tang Nanshan , is a biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation and diseases affecting the human immune system. Tanox took an innovative approach in developing an asthma drug that focused on the allergy-related basis of asthma, Xolair. In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. In 2007, Tanox was sold to Genentech for $919 million. Dr. Chang grew Tanox from an idea to a substantial publicly traded company, doing innovative science. Following her success with Tanox, she has become an angel investor in health-care entrepreneurships and performs philanthropic work in community health-education projects.

George Y. Wang, Sc.D. has served as Senior Technical Advisor and then Chief Technical Officer at Ansun Biopharma since April 2014. He was the Managing Director ofA-Bio Pharma Pte Ltd in charge of all operations from 2004 until 2008. Prior to that, he was at Tanox, Inc. from 1991 until 2002 and served as Vice President of Process Development and Production. Dr. Wang held various engineering positions at IDEC Pharmaceuticals, BP Amoco Corporation and MGI Pharmaceuticals, Inc. Dr. Wang received his Sc.D. in Biochemical Engineering from Massachusetts Institute of Technolog

Nancy Tang Chang (born 1950), née Tang Nanshan , is a biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation and diseases affecting the human immune system. Tanox took an innovative approach in developing an asthma drug that focused on the allergy-related basis of asthma, Xolair. In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. In 2007, Tanox was sold to Genentech for $919 million. Dr. Chang grew Tanox from an idea to a substantial publicly traded company, doing innovative science. Following her success with Tanox, she has become an angel investor in health-care entrepreneurships and performs philanthropic work in community health-education projects.